Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 18;14(22):5670.
doi: 10.3390/cancers14225670.

Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

Beatriz Rey-Búa  1 , Mónica Cabrero  1 , Leyre Bento  2 , Juan Montoro  3 , Mariana Bastos-Oreiro  4 , Rocío Parody  5 , Lucrecia Yañez  6 , Oriana Lopez-Godino  7 , Joud Zanabili  8 , Pilar Herrera  9 , Gonzalo Gutierrez  10 , Ariadna Perez  11 , Jose L Piñana  11 , Silvana Novelli  12 , María Cortés  13 , Ana Maria Sureda  5 , Dolores Caballero  1 , Alejandro Martín García-Sancho  1
Affiliations

Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

Beatriz Rey-Búa et al. Cancers (Basel). .

Abstract

Background: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored.

Methods: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival.

Results: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31-67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2-9.6).

Conclusions: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL.

Keywords: allogeneic stem cell transplantation; follicular lymphoma; non-Hodgkin lymphoma; transformed lymphoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Overall survival (OS) and (b) progression-free survival (PFS) in the global series.
Figure 1
Figure 1
(a) Overall survival (OS) and (b) progression-free survival (PFS) in the global series.
Figure 2
Figure 2
(a) Overall survival (OS) for reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens. (b) OS according to chronic graft-vs-host disease (cGVHD). (c) OS according to lymphoma status pre-alloSCT, complete response (CR) or other response.
Figure 2
Figure 2
(a) Overall survival (OS) for reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens. (b) OS according to chronic graft-vs-host disease (cGVHD). (c) OS according to lymphoma status pre-alloSCT, complete response (CR) or other response.
Figure 3
Figure 3
(a) Progression free-survival (PFS) for reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens. (b) PFS according to chronic graft-vs-host disease (cGVHD). (c) PFS according to lymphoma status pre-alloSCT, complete response (CR) or other response.
Figure 3
Figure 3
(a) Progression free-survival (PFS) for reduced-intensity conditioning (RIC) and myeloablative conditioning (MAC) regimens. (b) PFS according to chronic graft-vs-host disease (cGVHD). (c) PFS according to lymphoma status pre-alloSCT, complete response (CR) or other response.
Figure 4
Figure 4
Non-relapse mortality (NRM) in global series.
Figure 5
Figure 5
(a) Non-relapse mortality (NRM) for RIC and MAC regimens. (b) NRM for sibling vs. unrelated vs. haploidentical transplanta-tion.
See this image and copyright information in PMC

References

    1. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO Classification of Lymphoid Neoplasms and beyond: Evolving Concepts and Practical Applications. Blood. 2011;117:5019–5032. doi: 10.1182/blood-2011-01-293050. - DOI - PMC - PubMed
    1. Herold M., Haas A., Srock S., Neser S., Al-Ali H., Neubauer A., Dölken G., Naumann R., Knauf W., Freund M., et al. Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. J. Clin. Oncol. 2007;25:1986–1992. doi: 10.1200/JCO.2006.06.4618. - DOI - PubMed
    1. Marcus R., Imrie K., Solal-Celigny P., Catalano J., Dmoszynska A., Raposo J., Offner F., Gomez-Codina J., Belch A., Cunningham D., et al. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. J. Clin. Oncol. 2008;26:4579–4586. doi: 10.1200/JCO.2007.13.5376. - DOI - PubMed
    1. Salles G., Seymour J.F., Offner F., López-Guillermo A., Belada D., Xerri L., Feugier P., Bouabdallah R., Catalano J.V., Brice P., et al. Rituximab Maintenance for 2 Years in Patients with High Tumour Burden Follicular Lymphoma Responding to Rituximab plus Chemotherapy (PRIMA): A Phase 3, Randomised Controlled Trial. Lancet. 2011;377:42–51. doi: 10.1016/S0140-6736(10)62175-7. - DOI - PubMed
    1. Magnano L., Alonso-Alvarez S., Alcoceba M., Rivas-Delgado A., Muntañola A., Nadeu F., Setoain X., Rodríguez S., Andrade-Campos M., Espinosa-Lara N., et al. Life Expectancy of Follicular Lymphoma Patients in Complete Response at 30 Months Is Similar to That of the Spanish General Population. Br. J. Haematol. 2019;185:480–491. doi: 10.1111/bjh.15805. - DOI - PubMed